Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation

Area of Science:

• Pharmacology
• Clinical Medicine
• Cardiology

Background:

• Non-valvular atrial fibrillation (NVAF) management often involves anticoagulants.
• Dabigatran etexilate (DE) is a direct thrombin inhibitor used for NVAF.
• Understanding dabigatran plasma concentration variability is crucial for optimizing treatment and predicting outcomes.

Purpose of the Study:

• To assess dabigatran plasma concentration variability in Chinese NVAF patients.
• To identify factors influencing dabigatran concentration.
• To explore the association between dabigatran concentration and clinical events, particularly bleeding.

Main Methods:

• Prospective study involving 86 Chinese patients with NVAF on a fixed 110 mg DE dose.
• Measurement of steady-state dabigatran trough and peak plasma concentrations.
• Statistical analysis to identify covariates affecting concentration and predict clinical outcomes.

Main Results:

• Significant variability in dabigatran trough concentrations was observed.
• Age, Body Mass Index (BMI), and history of heart failure were significant covariates for dabigatran trough concentration.
• Dabigatran trough concentration and a history of hypertension were key predictors of bleeding events.

Conclusions:

• Dabigatran trough concentration exhibits substantial variability in Chinese NVAF patients.
• Factors like age, BMI, and heart failure history influence dabigatran levels.
• Elevated dabigatran trough concentration may independently predict bleeding risk in this population.